The company has effectively pledged its primary equity capital-raising vehicle (the ATM) to service a high-cost secured loan, leaving it with limited access to new equity capital until the notes are repaid. Monitor the stockholder meeting timeline and any Nasdaq listing compliance issues. The conversion terms (90% of 10-day VWAP floor) create significant potential dilution if the stock trades near the floor price.
Price Chart
Executive Summary
Co-Diagnostics filed an 8-K/A to correct the original 8-K by removing Maxim Group LLC as a party to the ATM Waterfall Distribution Agreement and adding an ATM Payment Direction Letter. The underlying transaction is a senior secured convertible loan from J.J. Astor & Co. for up to $3.1 million ($2.1 million funded initially), with a factor rate of 1.35x, secured by substantially all assets. All net proceeds from the company's existing ATM program (approx. $7.35M remaining capacity) are diverted to the lender under a waterfall structure until the notes are repaid, severely restricting the company's access to equity capital.
Key Facts
- Co-Diagnostics entered a loan agreement with J.J. Astor & Co. for up to $3.1 million; initial $2.1 million funded, net cash proceeds ~$2.016 million after 4% origination fee.
- The Initial Note has an original principal amount of $2.835 million (1.35x factor rate); an Additional Note of $1.35 million may be issued for an additional $1.0 million loan.
- 100% of net proceeds from the company's ATM program (approx. $7.35M remaining capacity) are directed to a DACA account controlled by the lender.
- Under the ATM waterfall: first $1.0M of ATM net proceeds goes to lender; then 80% to lender until weekly installments are met; then 25% to lender for remainder of week; after default, 80% to lender.
- The company must maintain ATM shares worth at least 200% of the outstanding principal amount of the notes.
- 600,000 commitment shares were issued to the lender at closing, subject to a make-whole provision if the stock closes below $0.218.
- The notes are convertible into common stock at a discount to VWAP (90% normally, 80% on default), subject to a floor price of 20% of the Nasdaq minimum price.
- The company must seek stockholder approval for issuances exceeding Nasdaq limits and must hold a stockholder meeting within ~40 days of funding.
- The filing is an amendment to correct the original 8-K; the original was filed on October 13, 2026.
Financial Impact
Up to $3.1M in loan proceeds ($2.1M funded initially, net ~$2.016M) secured by a senior lien on all assets. The ATM program (approx. $7.35M remaining capacity) is effectively pledged to repay the notes, with the company receiving only a portion of ATM proceeds after the lender is paid. The effective interest cost is a 1.35x factor rate on a 30-week repayment schedule, plus 600,000 commitment shares and potential dilution from conversion at a discount to market.
Risk Factors
- Potential significant dilution from conversion of notes at a discount to market price, with no cap on conversion shares beyond the floor price and Nasdaq limits.
- The ATM program is effectively unavailable for general corporate purposes until the notes are repaid, as all net proceeds are diverted to the lender.
- If the stock price declines, the ATM Coverage Requirement (200% of outstanding principal) may trigger further restrictions on cash flow to the company.
- The company must hold a stockholder meeting within ~40 days to authorize share issuances above Nasdaq limits, creating execution risk.
- Default triggers a 120% acceleration of principal, 19% default interest, and a more favorable conversion price (80% of VWAP) for the lender.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001493152-26-047089 |
| Exhibit: ex10-7.htm | 0001493152-26-047089 |
| Document: form8-ka.htm | 0001493152-26-047089 |
| Document: 0001493152-26-047089-index-headers.html | 0001493152-26-047089 |
| Document: 0001493152-26-047089-index.html | 0001493152-26-047089 |
| Document: 0001493152-26-047089.txt | 0001493152-26-047089 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5473 | awaiting T+20 | — | $0.4690 (+14.31%) |
Oct 15, 2026 12d ago | 8-K/A | $0.7151 | awaiting T+20 | — | $0.4690 (+34.41%) |
Oct 13, 2026 14d ago | 8-K | $1.07 | awaiting T+20 | — | $0.4690 (+55.96%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.4690 (−50.15%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.4690 (−50.15%) |
Sep 4, 2026 7w ago | DEFA14A | $1.16 $1.10 | ▼ −5.17% | ▼ −5.77% | $0.4690 (−59.57%) |
Sep 2, 2026 7w ago | EFFECT | $1.16 $1.07 | ▲ +7.76% | ▲ +7.68% | $0.4690 (+59.57%) |
Jul 31, 2026 12w ago | 8-K | $1.44 $1.21 | ▲ +15.97% | ▲ +18.96% | $0.4690 (+67.43%) |
Jul 27, 2026 13w ago | 424B5 | $1.41 $1.23 | ▲ +12.77% | ▲ +16.15% | $0.4690 (+66.74%) |
Jun 1, 2026 21w ago | EFFECT | $6.20 $3.10 | ▲ +50.00% | ▲ +48.70% | $0.4690 (+92.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers